New Delhi: Questions are also being raised over the efficacy of the Covaxin, being developed by Bharat Biotech along with the Indian Council for Medical Research and the National Institute of Virology, with several feeling that the government had rushed in to clear the vaccines without proper data on trials and safety.
Congress leader Shashi Tharoor said Covaxin has not yet completed Phase 3 trials and its approval was premature and could be dangerous. He added that its use should be avoided till the trials are complete, and India can start with the Oxford-AstraZeneca vaccine in the meantime. Congress leader Jairam Ramesh said, “Bharat Biotech is a first-rate enterprise, but it is puzzling that internationally-accepted protocols relating to Phase 3 trials are being modified for Covaxin. Health Minister should clarify.”
Vaccine scientist Dr Gagandeep Kang said she was “completely unaware of any data on efficacy of Bharat Biotech vaccine” adding “it will be a…